[
  {
    "headline": "q1 therapeutic earning united therapeutic nasdaq uthr impress",
    "text": "q1 earning season wrap let dig quarter good bad performer therapeutic industry include united therapeutic nasdaq uthr peer"
  },
  {
    "headline": "moderna inc mrna among good growth buy hold long term",
    "text": "recently compile list 12 good growth buy hold long term article go take look moderna inc nasdaq mrna stand growth bull case us close last week mostly lower however"
  },
  {
    "headline": "thermo fisher biogen gilead science moderna quidelortho trade need know",
    "text": "number jump afternoon session major pop nasdaq 3.4 p 500 2.5 response positive outcome u.s.-china trade negotiation side agree pause tariff 90 day signal potential turning point ongoing tension rollback cut u.s tariff chinese good 30 chinese tariff u.s import 10 give company breathe room reset inventory supply chain"
  },
  {
    "headline": "trump expect sign order slash drug",
    "text": "president trump expect sign executive order intend cut prescription drug order match drug overseas yahoo senior health reporter anjalee khemlani outline many step government agency involve investigate carry act watch expert insight analysis late action check morning brief nbsp"
  },
  {
    "headline": "moderna merge tech hr department",
    "text": "vaccine maker partner openai since 2023 rethink workforce plan thank grow capability ai tech"
  },
  {
    "headline": "moderna inc mrna among billionaire david e. shaw small cap pick huge upside potential",
    "text": "recently publish list billionaire david e. shaw 10 small cap pick huge upside potential article go take look moderna inc nasdaq mrna stand billionaire david e. shaw small cap pick huge upside potential david e. shaw one billionaire whose"
  },
  {
    "headline": "moderna nasdaqgs mrna expand ai ready collaboration benchle r transformation",
    "text": "moderna nasdaqgs mrna recently expand collaboration benchle enhance digital infrastructure foster research innovation despite positive development moderna fall 6 past month decline occur amid broad gain major u.s like nasdaq p 500 climbing due optimism around u.s.-uk trade deal rise cryptocurrency however moderna report decrease revenue significant net loss q1"
  },
  {
    "headline": "moderna present upcoming bernstein 41st annual strategic decision conference sdc may 29 2025",
    "text": "cambridge access newswire may 8 2025 moderna inc nasdaq mrna today announce participation follow upcoming conference bernstein 41st annual strategic decision conference sdc thursday may 29th 10 00am"
  },
  {
    "headline": "q1 earning recap abbvie nyse abbv top therapeutic",
    "text": "let dig relative performance abbvie nyse abbv peer unravel complete q1 therapeutic earning season"
  },
  {
    "headline": "therapeutic q1 result benchmarke sarepta therapeutic nasdaq srpt",
    "text": "end earning season always good time take step back see shine much let take look therapeutic fare q1 start sarepta therapeutic nasdaq srpt"
  },
  {
    "headline": "flagship pioneering national university singapore national university hospital national university health system announce collaboration advance biotech research development",
    "text": "flagship pioneering bioplatform innovation company yong loo lin school medicine national university singapore nus medicine national university hospital nuh national university health system nuhs today announce research development collaboration advance outcome human health sustainability flagship nus medicine nuh nuhs outline goal collaboration via memorandum understanding mou sign week"
  },
  {
    "headline": "moderna pharma fall fda name industry critic top vaccine regulator",
    "text": "dr vinay prasad succeed dr peter marks leave role leader fda center biologic evaluation research march"
  },
  {
    "headline": "moderna sharpens pipeline focus covid-19 vaccine demand ebb q1",
    "text": "moderna plan launch 10 new product next three year aim diversify revenue base still heavily reliant covid-19 vaccine sale"
  },
  {
    "headline": "3 cash heavy doghouse",
    "text": "company cash debt financially resilient mean strong lack leverage struggle grow generate consistent profit make unattractive borrower"
  },
  {
    "headline": "moderna nasdaqgs mrna report decrease q1 revenue net loss",
    "text": "moderna nasdaqgs mrna recently report decline revenue q1 2025 manage reduce net loss improve loss per despite company relatively flat last month performance align broad trend see significant gain due strong job report positive sentiment potential u.s.-china trade talk moderna result may add weight broad optimism minimal"
  },
  {
    "headline": "moderna mrna report q1 earning key metric say",
    "text": "headline number moderna mrna give insight company perform quarter end march 2025 may worthwhile compare key metric wall street estimate year ago actual"
  },
  {
    "headline": "moderna inc mrna q1 2025 earning call highlight navigating challenge strategic cost",
    "text": "despite significant revenue drop moderna inc mrna focus discipline pipeline growth drive future success"
  },
  {
    "headline": "q1 2025 moderna inc earning call",
    "text": "q1 2025 moderna inc earning call"
  },
  {
    "headline": "moderna cut cost covid sale slump",
    "text": "trim 2026 operating expense $ 500 q1 revenue plunge 35 $ 108"
  },
  {
    "headline": "moderna combination flu covid shot delay amid fda scrutiny",
    "text": "additional datum require fda late evidence one analyst describe high bar vaccine"
  },
  {
    "headline": "q1 therapeutic earning united therapeutic nasdaq uthr impress",
    "text": "q1 earning season wrap let dig quarter good bad performer therapeutic industry include united therapeutic nasdaq uthr peer"
  },
  {
    "headline": "moderna inc mrna among good growth buy hold long term",
    "text": "recently compile list 12 good growth buy hold long term article go take look moderna inc nasdaq mrna stand growth bull case us close last week mostly lower however"
  },
  {
    "headline": "thermo fisher biogen gilead science moderna quidelortho trade need know",
    "text": "number jump afternoon session major pop nasdaq 3.4 p 500 2.5 response positive outcome u.s.-china trade negotiation side agree pause tariff 90 day signal potential turning point ongoing tension rollback cut u.s tariff chinese good 30 chinese tariff u.s import 10 give company breathe room reset inventory supply chain"
  },
  {
    "headline": "trump expect sign order slash drug",
    "text": "president trump expect sign executive order intend cut prescription drug order match drug overseas yahoo senior health reporter anjalee khemlani outline many step government agency involve investigate carry act watch expert insight analysis late action check morning brief nbsp"
  },
  {
    "headline": "moderna merge tech hr department",
    "text": "vaccine maker partner openai since 2023 rethink workforce plan thank grow capability ai tech"
  },
  {
    "headline": "moderna inc mrna among billionaire david e. shaw small cap pick huge upside potential",
    "text": "recently publish list billionaire david e. shaw 10 small cap pick huge upside potential article go take look moderna inc nasdaq mrna stand billionaire david e. shaw small cap pick huge upside potential david e. shaw one billionaire whose"
  },
  {
    "headline": "moderna nasdaqgs mrna expand ai ready collaboration benchle r transformation",
    "text": "moderna nasdaqgs mrna recently expand collaboration benchle enhance digital infrastructure foster research innovation despite positive development moderna fall 6 past month decline occur amid broad gain major u.s like nasdaq p 500 climbing due optimism around u.s.-uk trade deal rise cryptocurrency however moderna report decrease revenue significant net loss q1"
  },
  {
    "headline": "moderna present upcoming bernstein 41st annual strategic decision conference sdc may 29 2025",
    "text": "cambridge access newswire may 8 2025 moderna inc nasdaq mrna today announce participation follow upcoming conference bernstein 41st annual strategic decision conference sdc thursday may 29th 10 00am"
  },
  {
    "headline": "q1 earning recap abbvie nyse abbv top therapeutic",
    "text": "let dig relative performance abbvie nyse abbv peer unravel complete q1 therapeutic earning season"
  },
  {
    "headline": "therapeutic q1 result benchmarke sarepta therapeutic nasdaq srpt",
    "text": "end earning season always good time take step back see shine much let take look therapeutic fare q1 start sarepta therapeutic nasdaq srpt"
  },
  {
    "headline": "flagship pioneering national university singapore national university hospital national university health system announce collaboration advance biotech research development",
    "text": "flagship pioneering bioplatform innovation company yong loo lin school medicine national university singapore nus medicine national university hospital nuh national university health system nuhs today announce research development collaboration advance outcome human health sustainability flagship nus medicine nuh nuhs outline goal collaboration via memorandum understanding mou sign week"
  },
  {
    "headline": "moderna pharma fall fda name industry critic top vaccine regulator",
    "text": "dr vinay prasad succeed dr peter marks leave role leader fda center biologic evaluation research march"
  },
  {
    "headline": "moderna sharpens pipeline focus covid-19 vaccine demand ebb q1",
    "text": "moderna plan launch 10 new product next three year aim diversify revenue base still heavily reliant covid-19 vaccine sale"
  },
  {
    "headline": "3 cash heavy doghouse",
    "text": "company cash debt financially resilient mean strong lack leverage struggle grow generate consistent profit make unattractive borrower"
  },
  {
    "headline": "moderna nasdaqgs mrna report decrease q1 revenue net loss",
    "text": "moderna nasdaqgs mrna recently report decline revenue q1 2025 manage reduce net loss improve loss per despite company relatively flat last month performance align broad trend see significant gain due strong job report positive sentiment potential u.s.-china trade talk moderna result may add weight broad optimism minimal"
  },
  {
    "headline": "moderna mrna report q1 earning key metric say",
    "text": "headline number moderna mrna give insight company perform quarter end march 2025 may worthwhile compare key metric wall street estimate year ago actual"
  },
  {
    "headline": "moderna inc mrna q1 2025 earning call highlight navigating challenge strategic cost",
    "text": "despite significant revenue drop moderna inc mrna focus discipline pipeline growth drive future success"
  },
  {
    "headline": "q1 2025 moderna inc earning call",
    "text": "q1 2025 moderna inc earning call"
  },
  {
    "headline": "moderna cut cost covid sale slump",
    "text": "trim 2026 operating expense $ 500 q1 revenue plunge 35 $ 108"
  },
  {
    "headline": "moderna combination flu covid shot delay amid fda scrutiny",
    "text": "additional datum require fda late evidence one analyst describe high bar vaccine"
  },
  {
    "headline": "moderna first quarter loss unexpectedly improve even revenue drop",
    "text": "moderna mrna first quarter loss unexpectedly improve year year drop expense help"
  },
  {
    "headline": "moderna drop political picture worsen",
    "text": "moderna lay plan thursday slash future cost effort stop bleed cash worsen political environment vaccine company make plan tough sell moderna stick prior guidance report quarterly loss $ 2.52 consensus estimate per loss $ 3.12 revenue $ 108 million line $ 106 million consensus estimate"
  },
  {
    "headline": "moderna beat q1 earning lag revenue focus cost cut",
    "text": "mrna report mixed q1 result company reiterate 2025 sale guidance announce cost cut initiative reduce expense significantly 2027"
  },
  {
    "headline": "wayfair beat estee lauder outlook moderna trend ticker",
    "text": "wayfair w gain report surprise earning beat company say business model minimize tariff impact estee lauder el warn slowdown sale 2025 expect return growth 2026 assume clarity trump tariff policy moderna mrna announce plan cut $ 1.5 billion report 35 drop revenue year ago period watch expert insight analysis late action check wealth"
  },
  {
    "headline": "moderna crumble vaccine trouble rattle topline",
    "text": "moderna crumble thursday biotech company miss sale estimate two product spikevax mresvia"
  },
  {
    "headline": "moderna mrna report q1 loss lag revenue estimate",
    "text": "moderna mrna deliver earning revenue surprise 13.70 14.95 respectively quarter end march 2025 number hold clue lie ahead"
  },
  {
    "headline": "moderna nasdaq mrna miss q1 revenue estimate",
    "text": "biotechnology company moderna nasdaq mrna miss wall street revenue expectation q1 cy2025 sale fall 35.3 year year $ 108 million company full year revenue guidance $ 2 billion midpoint come 6.1 analyst estimate gaap loss $ 2.52 per 18.6 analyst consensus estimate"
  },
  {
    "headline": "moderna post loss cite seasonality respiratory business",
    "text": "moderna log first quarter loss revenue fall drag low product sale though company say expect demand increase cold flu season later year"
  },
  {
    "headline": "moderna q1 earning snapshot",
    "text": "mrna thursday report loss $ 971 million first quarter cambridge massachusetts base company say loss $ 2.52 per result top wall street expectation"
  },
  {
    "headline": "moderna say fda constructive delay flu covid shot",
    "text": "reuters -moderna thursday push back time frame likely approval combination vaccine mean protect covid-19 influenza say exchange u.s drug regulator remain constructive health secretary vaccine skeptic robert f. kennedy jr u.s vaccine maker report first quarter profit sale beat wall street estimate company cost cut effort offset wane post pandemic demand covid shot company batter decline covid revenue well political concern spur kennedy appointment fall 3.3 $ 27.60 morning"
  },
  {
    "headline": "moderna report first quarter 2025 result provide business update",
    "text": "report first quarter revenue $ 0.1 billion gaap net loss $ 1.0 billion gaap eps $ 2.52 reiterate 2025 expect revenue range $ 1.5 $ 2.5 billion 2025 year end cash balance approximately $ 6 billion announce reduction"
  },
  {
    "headline": "moderna inc mrna among bad perform p 500 far 2025",
    "text": "recently publish list 11 bad perform p 500 far 2025 article take look moderna inc nasdaq mrna stand bad perform year two year surge 53 mark good performance broad since"
  },
  {
    "headline": "moderna mrna report earning tomorrow expect",
    "text": "biotechnology company moderna nasdaq mrna announce earning result tomorrow hour need know"
  },
  {
    "headline": "analyst estimate pacira pcrx report decline earning look",
    "text": "pacira pcrx possess right combination two key ingredient likely earning beat upcoming report get prepare key expectation"
  },
  {
    "headline": "36 moderna buy dip",
    "text": "major pandemic star biotech moderna nasdaq mrna also seem disappear world attention mean moderna inactive fact quite opposite moderna shoot prominence near end 2021 spikevax coronavirus vaccine receive emergency use authorization eua u.s food drug administration fda"
  }
]